Compare · GRCE vs NVO
GRCE vs NVO
Side-by-side comparison of Grace Therapeutics Inc. (GRCE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GRCE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 6216.0x GRCE ($30.9M).
- Over the past year, GRCE is down 28.3% and NVO is down 43.1% - GRCE leads by 14.7 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 1 for GRCE).
- NVO has more recent analyst coverage (25 ratings vs 1 for GRCE).
- Company
- Grace Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $2.30-3.77%
- $42.94-1.84%
- Market cap
- $30.9M
- $191.82B
- 1M return
- -3.36%
- -6.14%
- 1Y return
- -28.35%
- -43.10%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 7
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GRCE
- Grace Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13G/A filed by Grace Therapeutics Inc.
- Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Grace Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
- Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
- Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences
- Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
- Grace Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates